Cytological DNA methylation for cervical cancer screening: a validation set

Area of Science:

• Gynecologic Oncology
• Molecular Diagnostics
• Cancer Screening

Background:

• Previous studies established cutoff values for EPB41L3 and JAM3 gene methylation for detecting cervical intraepithelial neoplasia grade 2 or worse (CIN2+).
• This validation trial assessed the utility of DNA methylation in cervical cytology for screening CIN2+ in an unselected population.

Purpose of the Study:

• To evaluate the diagnostic accuracy of DNA methylation assays and hrHPV genotyping for detecting CIN2+.
• To compare the performance of methylation assays against hrHPV testing in cervical cancer screening.

Main Methods:

• Collected liquid-based cervical swab samples for methylation assays and hrHPV testing.
• Assessed diagnostic accuracy based on confirmed histology results.
• Analyzed sensitivity, specificity, and predictive values for CIN2+ detection.

Main Results:

• The methylation assay demonstrated lower sensitivity (68.7%) but significantly higher specificity (96.7%) for CIN2+ compared to hrHPV testing.
• The assay showed favorable performance in hrHPV-negative patients and those with cervical adenocarcinoma.
• DNA methylation assay exhibited superior specificity (100%) for detecting residual CIN2+ compared to hrHPV testing.

Conclusions:

• The EPB41L3 and JAM3 gene methylation assay offers favorable diagnostic accuracy and high specificity for CIN2+ detection.
• This methylation assay is a promising triage or independent tool for cervical cancer screening.
• Cervical DNA methylation status may serve as a prognostic biomarker and warrants further investigation for endometrial carcinoma detection.